Eterna has in-licensed a portfolio of over 130 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system from Factor Bioscience.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze